Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei...
-
Upload
cecily-washington -
Category
Documents
-
view
222 -
download
5
Transcript of Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei...
![Page 1: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/1.jpg)
Diabetes Mellitus, MetabolismJournal Club
November 27, 2008
Rei Suganaga, MD
Diabetes and Endocrine Department,
Kameda Medical Center
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein, The primary objective of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)NEJM; Nov 20, 2008 vol. 359 no. 21
Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes, A Randomized Controlled Trial The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trialJAMA, November 12, 2008 Vol 300, No. 18
![Page 2: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/2.jpg)
Rosuvastatin to Prevent Vascular Events in Men and Women
with Elevated C-Reactive Protein
The primary objective of the Justification for the Use of
Statins in Prevention: an Intervention Trial Evaluating
Rosuvastatin (JUPITER)
NEJM; Nov 20, 2008 vol. 359 no. 21
![Page 3: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/3.jpg)
Background・血管病変や糖尿病、高脂血症患者には MI 、 stroke 、 death from CV cause の予防に statin が推奨され
ている。・しかし実際、 MI や Stroke の半数が正常 LDL 患者に発症してい
る。
・高感度 CRP の測定が future vascular events の独立予測因子であり LDL 値に関わらずリスク改善効果がある。・すでに statin が高感度 CRP 減少効果ありとの報告あり。
・「正常 LDL だが高感度 CRP 上昇患者」 に対する statin 加療の利益について、前向き研究はない。・ JUPITER では rosuvastatin20mg/day 投与での CV events について分析した。
![Page 4: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/4.jpg)
Methods
■ A randomized, double-blind, placebo-controlled,
multicenter trial conducted at 1315 sites in 26 countries
・ intention-to-treat basis
■ Inclusion Criteria
・ did not have a Hx of cardiovascular disease • LDL≦130 mg/dl and high-sensitivity CRP≧ 2.0 mg/l• a willingness to participate for the duration of the trial • TG ≦ 500 mg/dl
![Page 5: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/5.jpg)
Methods■ Exclusion criteria:・ previous or current use of lipid-lowering therapy,
・ current use of postmenopausal HRT
・ hepatic dysfunction , CK ↑, Cr >2,0mg/dl
・ sBP>190 or dBP >100
・ cancer within 5 years before
・ uncontrolled hypothyroidism
・ a recent Hx of alcohol or drug abuse or another medical
![Page 6: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/6.jpg)
Methods■Trial Protocol
randomly assigned in a 1:1 ratio to receive either
・ Rosuvastatin 20 mg daily,
・ Placebo
Follow-up visits : occur at 13weeks and then
6, 12, 18, 24, 30, 36, 42, 48, 54,60 months after randomize
![Page 7: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/7.jpg)
End points
■Primary outcome• occurrence of a first major cardiovascular event,
defined as nonfatal MI, nonfatal stroke,
hospitalization for unstable angina,
an arterial revascularization procedure,
or confirmed death from cardiovascular causes.
■Secondary end points • the components of the primary end point
considered individually and death from any cause.
![Page 8: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/8.jpg)
Results■ Baseline Characteristics
・ Feb 4, 2003 ~ Dec 15, 2006
・ 89,800 enrollment → 72,088 ineligible (80.2%) (LDL>130(52.2%), CRP
<2.0(36.1%))
→ 17,802 assigned
Rosuvastatin ; 8,901
Placebo ; 8,901
![Page 9: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/9.jpg)
![Page 10: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/10.jpg)
![Page 11: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/11.jpg)
Results■Effect of Rosuvastatin
・ Compliance; 75%
-37%
-50%
+4%
-17%
![Page 12: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/12.jpg)
Results■End points
・ median follow-up ; 1.9 years (max 5.0 years)
・ first major CV event ; 142 Rosuvastatin vs 251 placebo
![Page 13: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/13.jpg)
![Page 14: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/14.jpg)
NNT
NNT: 95 31 ・・ 25 (2years)
(4years) (5years)
![Page 15: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/15.jpg)
Results
■Subgroup analyses
![Page 16: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/16.jpg)
![Page 17: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/17.jpg)
Results
■Adverse events
![Page 18: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/18.jpg)
![Page 19: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/19.jpg)
Conclusions□Among apparently healthy men & women
who didn’t have HL but have elevated level of CRP,
・ Rosuvastatin significantly reduced the incidence of major CV events, and death from any cause.
・ Consistent effects were observed in all sub-groups
・ no significant increase about adverse events
![Page 20: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/20.jpg)
Limitations
1. Not include people with low level of CRP
2. Short follow-up time
→longer-term therapy should be considered.
![Page 21: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/21.jpg)
![Page 22: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/22.jpg)
Low-Dose Aspirin for Primary Preventionof Atherosclerotic Events
in Patients With Type 2 Diabetes
A Randomized Controlled Trial
The Japanese Primary Prevention of Atherosclerosis
With Aspirin for Diabetes (JPAD) trial
JAMA, November 12, 2008 Vol 300, No. 18
![Page 23: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/23.jpg)
Background・糖尿病は心血管障害の大きなリスク因子である。 Framingham Heart Study ; Odds Ratios
-Coronary heart disease( 男・女 ) ; 1.5 ・ 1.8 -Stroke:1.4 ・ 1.7
・ aspirin は心血管障害の一次及び二次予防として確立してる。・糖尿病に代表されるような心血管障害のリスク因子をもつ患者に
は 禁忌事項がない限り asprin 投与が推奨されている。 ADA ; recommend use of aspirin for DM + α
(α ; 40y.o.<, Fx of coronary , HTN, smoke, HL, UAE)
・しかし糖尿病患者に対する予防効果としてはこれまでの大規模研究
/ サブグループ解析でも証明されていない。・そのため糖尿病患者の一次予防としての aspirin 効果について 前向き研究を行った。
![Page 24: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/24.jpg)
Methods
■ The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial
■A prospective, randomized, open-label, controlled trial with blinded end-point assessment.
・ Patients were enrolled and followed up at 163 institutions throughout Japan.
![Page 25: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/25.jpg)
Methods
■ Inclusion Criteria
• Dx of type 2 DM
• Age 30 – 85
• ability to provide informed consent.
![Page 26: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/26.jpg)
Methods■ Exclusion criteria:• ECG changes(ST↑↓,Qwave)• Hx of coronary heart disease(confirmed by angiography)
• Hx of cerebrovascular disease• Hx of arteriosclerotic disease• Af ・ Pregnancy • Use of antiplatelet or antithrombotic therapy• Hx of severe gastric or duodenal ulcer;• Severe liver/renal dysfunction ・ allergy to aspirin.
![Page 27: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/27.jpg)
Methods■Trial Protocol
randomly assigned
• 81 mg or 100 mg of aspirin once daily.
• Non aspirin group
• Follow-up visits : every 2 weeks for patients seen in a clinic setting
every 4 weeks for patients seen in a hospital setting
• Non aspirin group were allowed to use antiplatelet/thrombotic therapy,
including aspirin, if needed and vice versa.
![Page 28: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/28.jpg)
End points■Primary outcome• any atherosclerotic event
• sudden death(coronary,cerebrovascular, and aortic causes)
• nonfatal AMI; AP; newly developed exertional angina
• nonfatal ischemic and hemorrhagic stroke; TIA
• nonfatal aortic and peripheral vascular disease
(ASO,dissection, mesenteric arterial thrombosis)
■Secondary end points • each primary end point
• Combinations of primary end points
• death from any cause.
![Page 29: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/29.jpg)
Adverse events
■Adverse events• gastrointestinal (GI) events
• any hemorrhagic events other than hemorrhagic stroke
![Page 30: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/30.jpg)
Results・ screened Dec 2002- May 2005 ・ follow-up until Apr 2008
・ median follow-up; 4.37years
■study population
![Page 31: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/31.jpg)
![Page 32: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/32.jpg)
![Page 33: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/33.jpg)
Results■ Baseline Characteristics
・ 2,567 screened →2539 randomized
・ aspirin 1262 vs nonaspirin1262
・ 193 lost to follow-up
・ median follow-up; 4.37years
By the end of the study
・ aspirin group;123(10%) patients had stopped taking Med
・ nonaspirin group; 6(0.5%) aspirin,
3(0.2%) other antiplatelet
![Page 34: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/34.jpg)
Results・ total 154 events occurred
・ primary end point; there is no significant difference
・ secondary - ; fatal coronary and cerebrovascular events
> significantly (P=.0037)
![Page 35: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/35.jpg)
Results■Subgroup Analyses ・ 65 ≦ ; the events was significantly lower in aspirin group
(HR 0.68 , 32% relative reduction)
・ other subgroup show non-significant difference.
![Page 36: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/36.jpg)
Results
■Adverse events
![Page 37: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/37.jpg)
![Page 38: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/38.jpg)
Results
■Adverse events ・ serious bleeding that required transfusion
asipirin; 4 vs nonasipirin; 0
・ But no increase in hemorrhagic strokes
in aspirin group
![Page 39: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/39.jpg)
Limitations
1. Did not have advantages of a double-blind, randomized. (prospective, randomized, open-label, controlled trial
with blinded end-point assessment)
2. Event rate was low and the study was underpowered
→larger trial is needed to determine the efficacy
![Page 40: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/40.jpg)
Conclusions□JPAD trial is the first prospectively designed trial to evaluate the
efficacy of low-dose aspirin for the primary prevention of atherosclerotic events in patients with type2 DM
・ Low-dose aspirin as primary prevention didn’t reduce the risk of cardiovascular events.
-As for fatal coronary and cerebrovascular events,
low-dose aspirin reduced the events significantly(P=.0037 HR0.10)
-65≦ ; 32% relative reduction in total atherosclerotic events
・ no increase in hemorrhagic strokes
but a small increase in serious GI hemorrhagic events
![Page 41: Diabetes Mellitus, Metabolism Journal Club November 27, 20 08 Rei Suganaga, MD Diabetes and Endocrine Department, Kameda Medical Center Rosuvastatin to.](https://reader035.fdocuments.us/reader035/viewer/2022062408/56649f055503460f94c1af6b/html5/thumbnails/41.jpg)